Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AeroRx Therapeutics

Request full access

Nebulized combination therapies for chronic respiratory diseases

San Diego, United StatesFounded 2023Biotech & Life Sciences

About AeroRx Therapeutics

AeroRx Therapeutics is a clinical-stage biopharmaceutical firm founded in 2022, located in La Jolla, California. The company spun off from iPharma Lab's inhalation contract development and research business. It is focused on creating proprietary, nebulized combination drug products to treat chronic respiratory diseases, particularly Chronic Obstructive Pulmonary Disease (COPD). The company's business model centers on developing these therapies through clinical trials and seeking regulatory approval to bring them to market, addressing a significant portion of the COPD population that is poorly served by existing handheld inhalers.

The co-founder and CEO, Ahmet Tutuncu, M.D., Ph.D., is a clinician and scientist with over three decades of experience in the pharmaceutical industry, focusing on respiratory and critical care. His background includes co-founding Patara Pharma and Elevation Pharma, both of which were acquired, and leading development activities for three successful NDAs/MAAs for respiratory treatments. Another co-founder is Keith Ung, who serves as the company's President.

AeroRx's lead product candidate is AERO-007, the first nebulized LABA/LAMA (long-acting beta-agonist/long-acting muscarinic antagonist) fixed-dose combination therapy in development for COPD. It combines two FDA-approved bronchodilators, indacaterol and glycopyrrolate, in a proprietary formulation delivered via a standard jet nebulizer. This approach targets patients who struggle with handheld inhalers, which can be difficult to use correctly, leading to suboptimal dosing for up to 75% of users. Nebulized delivery provides a passive-breathing alternative designed to ensure more consistent and effective dosing, especially for older adults and those with advanced COPD. In October 2025, AeroRx announced a $21 million Series A financing led by Avalon BioVentures to advance AERO-007 into late-stage clinical development, following positive Phase 2a trial data that showed the treatment was well-tolerated and provided rapid, sustained 24-hour bronchodilation. The company also has a second program, AERO-111, in development as the first potential nebulized LABA/LAMA/ICS (inhaled corticosteroid) triple therapy for patients requiring treatment escalation.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
58.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Drug Development, Respiratory, Chronic Disease, Pulmonary, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Oct 2025 $1M $105M The Conrad Prebys Foundation ↗
SERIES A✓Equity / VC Oct 2025 $21M $84M Correlation Ventures · Avalon BioVentures · Alexandria Venture Investments ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

AeroRx Therapeutics website traffic

Latest recorded traffic for AeroRx Therapeutics is 1.3K monthly website visits.

Latest monthly visits1.3K
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AeroRx Therapeutics in the San Diego ecosystem

Live from Dealroom

The AeroRx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • The Conrad Prebys Foundation
  • Avalon BioVentures
  • Correlation Ventures
  • Alexandria Venture Investments
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AeroRx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AeroRx Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.